Revenue missed consensus by ~21%, but the miss is likely due to the consensus being stale or misaligned with quarterly cadence. The FY guidance of >$1B (including $40M Regeneron payment) implies H2 acceleration. Watch for FDA decisions on Pixclara (PDUFA Sept 11, 2026) and Zircaix BLA resubmission. The $600M convertible refinancing removes near-term debt overhang. The Regeneron deal provides non-dilutive capital and validates platform technology.
Price Chart
Executive Summary
Telix reported Q2 2026 revenue of $247M, up 21% YoY and 7% QoQ, driven by Precision Medicine growth. The company expects FY 2026 revenue and other income to exceed $1B, tracking the upper end of guidance. R&D guidance was raised to $230-270M to accelerate pipeline programs, and a $600M convertible bond refinancing was completed.
Key Financial Metrics
Key Facts
- Q2 2026 revenue $247M, up 21% YoY and 7% QoQ
- Precision Medicine revenue $202M, up 30% YoY and 9% QoQ
- FY 2026 revenue guidance tracking upper end of $950M-$970M, plus $40M non-refundable Regeneron payment
- R&D expenditure guidance raised to $230M-$270M
- Completed $600M convertible bond refinancing, extending maturities to 2031
- FDA alignment on ProstACT Global Phase 3 trial for TLX591-Tx in mCRPC
- Regeneron strategic collaboration for next-gen radiopharmaceutical therapies
- Three new Non-Executive Directors appointed
Financial Impact
Q2 revenue $247M vs consensus $311.6M (miss), but FY guidance raised to >$1B including $40M Regeneron payment; R&D spend increased by $40-80M
Risk Factors
- Revenue miss vs consensus may pressure near-term sentiment
- R&D spend increase to $230-270M could pressure margins
- Regulatory risk: FDA decisions on Pixclara, Zircaix, and TLX591-Tx IND
- Convertible bond refinancing adds $600M debt, though at longer maturity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3330166 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $12.83 $11.95 | ▼ −6.86% | ▼ −8.99% | $10.55 (−17.77%) |
Sep 14, 2026 18d ago | Press Release | $11.78 $11.31 | ▼ −3.99% | ▼ −4.10% | $10.55 (−10.44%) |
Sep 2, 2026 4w ago | 6-K | $11.45 $11.90 | ▲ +3.93% | ▲ +4.89% | $10.55 (−7.86%) |
Sep 1, 2026 4w ago | Press Release | $11.45 $11.90 | ▲ +3.93% | ▲ +4.89% | $10.55 (−7.86%) |
Aug 20, 2026 6w ago | 6-K | $12.42 $11.38 | ▼ −8.41% | ▼ −9.53% | $10.55 (−15.06%) |
Aug 20, 2026 6w ago | Press Release | $12.42 $11.38 | ▼ −8.41% | ▼ −9.53% | $10.55 (−15.06%) |
Jul 30, 2026 9w ago | Press Release | $9.89 $11.52 | ▲ +16.48% | ▲ +12.97% | $10.55 (+6.67%) |
Jul 21, 2026 10w ago | Press Release | $10.32 $10.10 | ▼ −2.13% | ▲ +0.27% | $10.55 (+2.23%) |
Jul 21, 2026 10w ago | 6-K | $10.92 $9.98 | ▼ −8.61% | ▼ −7.38% | $10.55 (−3.39%) |
Jul 20, 2026 10w ago | Press Release | $10.92 $9.98 | ▼ −8.61% | ▼ −7.38% | $10.55 (−3.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access